Nexell Sues Sublicensee Miltenyi In Defense Of Stem Cell Purification Patents
This article was originally published in The Gray Sheet
Nexell Therapeutics' second move to defend patents covering the firm's proprietary stem cell purification technology kicked off with the recent filing of a patent suit in Delaware federal court.
You may also be interested in...
FDA should clarify whether an exemption in U.S. patent law protects AmCell Corp. from a patent infringement suit by Nexell Therapeutics, according to a summary judgment by the federal district court in Wilmington, Delaware.
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.